BG104689A - Pharmaceutical preparations for selectively supplementing oestrogen deficiency in the central nervous system - Google Patents

Pharmaceutical preparations for selectively supplementing oestrogen deficiency in the central nervous system

Info

Publication number
BG104689A
BG104689A BG104689A BG10468900A BG104689A BG 104689 A BG104689 A BG 104689A BG 104689 A BG104689 A BG 104689A BG 10468900 A BG10468900 A BG 10468900A BG 104689 A BG104689 A BG 104689A
Authority
BG
Bulgaria
Prior art keywords
central nervous
oestrogen
transcription
nervous system
estradiol
Prior art date
Application number
BG104689A
Other languages
Bulgarian (bg)
English (en)
Inventor
Vladimir Patchev
Michael Oettel
Ina Thieme
Sigfrid Schwarz
Wolfgang Romer
Original Assignee
Jenapharm Gmbh & Co. Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE1998121831 external-priority patent/DE19821831A1/de
Application filed by Jenapharm Gmbh & Co. Kg filed Critical Jenapharm Gmbh & Co. Kg
Publication of BG104689A publication Critical patent/BG104689A/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BG104689A 1998-02-20 2000-08-15 Pharmaceutical preparations for selectively supplementing oestrogen deficiency in the central nervous system BG104689A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19807264 1998-02-20
DE1998121831 DE19821831A1 (de) 1998-05-15 1998-05-15 Pharmazeutische Präparate zur gezielten Substitution des Estrogenmangels im Zentralnervensystem
PCT/DE1999/000353 WO1999042108A1 (de) 1998-02-20 1999-02-10 Pharmazeutische präparate zur gezielten substitution des estrogenmangels im zentralnervensystem

Publications (1)

Publication Number Publication Date
BG104689A true BG104689A (en) 2001-04-30

Family

ID=26044035

Family Applications (1)

Application Number Title Priority Date Filing Date
BG104689A BG104689A (en) 1998-02-20 2000-08-15 Pharmaceutical preparations for selectively supplementing oestrogen deficiency in the central nervous system

Country Status (24)

Country Link
EP (1) EP1056460B1 (xx)
JP (1) JP2002503694A (xx)
KR (1) KR20010041107A (xx)
CN (1) CN1291102A (xx)
AT (1) ATE252388T1 (xx)
AU (1) AU739071C (xx)
BG (1) BG104689A (xx)
BR (1) BR9909205A (xx)
CA (1) CA2321498A1 (xx)
CZ (1) CZ291764B6 (xx)
DE (1) DE59907446D1 (xx)
EA (1) EA002707B1 (xx)
EE (1) EE03906B1 (xx)
HU (1) HUP0100742A3 (xx)
ID (1) ID27069A (xx)
IL (1) IL137727A0 (xx)
IS (1) IS5571A (xx)
NO (1) NO20004153L (xx)
NZ (1) NZ506049A (xx)
PL (1) PL342313A1 (xx)
SK (1) SK12152000A3 (xx)
TR (1) TR200002400T2 (xx)
UA (1) UA57830C2 (xx)
WO (1) WO1999042108A1 (xx)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2253318T3 (es) * 2001-11-07 2006-06-01 Schering Ag Cribado in vitro de ligandos del receptor de estrogeno.
CN112189624A (zh) * 2020-09-08 2021-01-08 山东第一医科大学(山东省医学科学院) 一种利用受体基因沉默技术构建和鉴定女性ad模型的方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4897389A (en) * 1984-10-29 1990-01-30 Chaovanee Aroonsakul Treating central nervous system diseases
US4791099A (en) * 1984-10-29 1988-12-13 Chaovanee Aroonsakul Method of treatment for central nervous system diseases such as Alzheimer's's disease
DE4239946C2 (de) * 1992-11-27 2001-09-13 Jenapharm Gmbh Estranderivate mit einer 14alpha,15alpha-Methylengruppe und Verfahren zu ihrer Herstellung
US5554601A (en) * 1993-11-05 1996-09-10 University Of Florida Methods for neuroprotection
DE4338314C1 (de) * 1993-11-10 1995-03-30 Jenapharm Gmbh Pharmazeutische Präparate zur Prophylaxe und Therapie radikalvermittelter Zellschädigungen
DE4429397C2 (de) * 1994-08-09 2003-11-20 Jenapharm Gmbh Estra-1,3,5(10)-trien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
DE19524937A1 (de) * 1995-07-08 1997-01-09 Jenapharm Gmbh Pharmazeutische Präparate zur Prophylaxe und Therapie radikalvermittelter Zellschädigungen und zur medikamentösen Substitution beim Mann
WO1997003661A1 (en) * 1995-07-24 1997-02-06 University Of Florida Research Foundation, Incorporated Use of non-estrogen polycyclic phenol compounds for the manufacture of a medicament for conferring neuroprotection to cells

Also Published As

Publication number Publication date
PL342313A1 (en) 2001-06-04
EP1056460B1 (de) 2003-10-22
CN1291102A (zh) 2001-04-11
EE200000477A (et) 2001-12-17
KR20010041107A (ko) 2001-05-15
AU2920999A (en) 1999-09-06
NZ506049A (en) 2002-09-27
CZ291764B6 (cs) 2003-05-14
JP2002503694A (ja) 2002-02-05
DE59907446D1 (de) 2003-11-27
EA002707B1 (ru) 2002-08-29
CZ20002938A3 (cs) 2001-01-17
WO1999042108A1 (de) 1999-08-26
TR200002400T2 (tr) 2000-11-21
EP1056460A1 (de) 2000-12-06
CA2321498A1 (en) 1999-08-26
ATE252388T1 (de) 2003-11-15
NO20004153L (no) 2000-10-09
HUP0100742A3 (en) 2002-07-29
UA57830C2 (uk) 2003-07-15
IL137727A0 (en) 2001-10-31
ID27069A (id) 2001-02-22
EA200000858A1 (ru) 2001-04-23
IS5571A (is) 2000-07-24
SK12152000A3 (sk) 2001-02-12
BR9909205A (pt) 2000-11-14
EE03906B1 (et) 2002-12-16
NO20004153D0 (no) 2000-08-18
HUP0100742A2 (hu) 2001-09-28
AU739071C (en) 2002-04-11
AU739071B2 (en) 2001-10-04

Similar Documents

Publication Publication Date Title
WO1998027929A3 (de) Therapeutische gestagene zur behandlung von premenstrual dysphoric disorder
WO1996019568A3 (en) Stabilized ribozyme analogs
HUP0102483A2 (hu) Androszt-5-én-3béta, 17béta-diolt tartalmazó gyógyszerkészítmények
MX9700223A (es) Composicion farmaceutica para la liberacion controlada de moguisteina en una suspension liquida.
PL323046A1 (en) Procedures related to arterio-vascular and vascular transplants: method and compositions
CA2337991A1 (en) Benzocycloheptenes, process for their production, pharmaceutical preparations that contain the latter as well as their use for the production of pharmaceutical agents
DE59510626D1 (de) Verwendung von kompetitiven progesteronantagonisten für die herstellung von arzneimitteln zur behandlung von dysfunktionellen uterinen blutungen
NZ271363A (en) Use of antiglucocorticoid steroids to treat anxiety disorders
HUT72670A (en) Containing galanthamine pharmaceutical composition for treating nicotine dependence
MY137435A (en) Retinoid compounds (i)
ATE381533T1 (de) Pharmazeutisch wirksame verbindungen und methoden zu ihrer anwendung
NZ333232A (en) Use of p-aminophenol derivatives (paracetamol) to treat neurodegenerative disease
BG102660A (en) Combined pharmaceutical preparation of lhrh-analogues and antiesterogens for the treatment of gynaecological disorders
BG104689A (en) Pharmaceutical preparations for selectively supplementing oestrogen deficiency in the central nervous system
GR3025872T3 (en) Orally active derivatives of 1,3,5(10)-estratriene
MX9800049A (es) Antraquinonas mono- y disulfo-substituidas y su uso para el tratamiento de trastornos de la matriz del hueso.
WO1994024279A3 (en) Agents for the prevention and treatment of huntington's disease and other neurological disorders
AU8624198A (en) 11beta-aryl substituted 14,17-ethano-oestratriens, method for the production of these compounds and their use in the production of medicaments.
CA2421302A1 (en) 4-halogenated 17-methylene steroids, method for the production thereof and pharmaceutical compositions containing these compounds
Romanenkova Regional demographic policy: goals, principles, possible solutions
MX9800697A (es) Uso de glicosidos de calendula para el tratamiento de psoriasis.